event,time
"nd PJ, White DJ, et al. The piggyback operation for liver transplantation. Surg Gynecol Obstet. 1988;167:407–415.3. Calne RY, Friend PJ, Spalding J, et al. Piggyback liver transplantation: a new technique. Lancet. 1988;1:1183–1185.4. Li Y, Li Y, Li Y, et al. Liver transplantation for hepatocellular carcinoma in China: a report from the Chinese liver transplantation registry. Liver Transpl. 2013;19:1021–1029.5. Burdick JS, Klintmalm GB, Knechtle SJ, et al. Graft-versus-host disease after liver transplantation. Transplantation. 1988;46:722–724.6. Klintmalm GB, Burdick JS, Knechtle SJ, et al. Graft-versus-host disease after liver transplantation. Transplantation. 1988;46:722–724.7. Klintmalm GB, Burdick JS, Knechtle SJ, et al. Graft-versus-host disease after liver transplantation. Transplantation. 1988;46:722–724.8. Klintmalm GB, Burdick JS, Knechtle SJ, et al. Graft-versus-host disease after liver transplantation. Transplantation. 1988;46:722–724.9. Klintmalm GB, Burdick JS, Knechtle SJ, et al. Graft-versus-host disease after liver transplantation. Transplantation. 1988;46:722–724.10. Klintmalm GB, Burdick JS, Knechtle SJ, et al. Graft-versus-host disease after liver transplantation. Transplantation. 1988;46:722–724.11. Elfeki M, Al-Harbi S, Al-Harbi A, et al. Graft-versus-host disease after liver transplantation: a single-center experience. Saudi J Gastroenterol. 2015;21:105–109.12. Murali AR, Klintmalm GB, Knechtle SJ, et al. Graft-versus-host disease after liver transplantation: a single-center experience. Transplantation. 1994;57:1225–1229.13. Murali AR, Klintmalm GB, Knechtle SJ, et al. Graft-versus-host disease after liver transplantation: a single-center experience. Transplantation. 1994;57:1225–1229.14. Murali AR, Klintmalm GB, Knechtle SJ, et al. Graft-versus-host disease after liver transplantation: a single-center experience. Transplantation. 1994;57:1225–1229.15. Murali AR, Klintmalm GB, Knechtle SJ, et al. Graft-versus-host disease after liver transplantation: a single-center experience. Transplantation. 1994;57:1225–1229.16. Murali AR, Klintmalm GB, Knechtle SJ, et al. Graft-versus-host disease after liver transplantation: a single-center experience. Transplantation. 1994;57:1225–1229.17. Murali AR, Klintmalm GB, Knechtle SJ, et al. Graft-versus-host disease after liver transplantation: a single-center experience. Transplantation. 1994;57:1225–1229.18. Murali AR, Klintmalm GB, Knechtle SJ, et al. Graft-versus-host disease after liver transplantation: a single-center experience. Transplantation. 1994;57:1225–1229.19. Murali AR, Klintmalm GB, Knechtle SJ, et al. Graft-versus-host disease after liver transplantation: a single-center experience. Transplantation. 1994;57:1225–1229.20. Murali AR, Klintmalm GB, Knechtle SJ, et al. Graft-versus-host disease after liver transplantation: a single-center experience. Transplantation. 1994;57:1225–1229.21. Murali AR, Klintmalm GB, Knechtle SJ, et al. Graft-versus-host disease after liver transplantation: a single-center experience. Transplantation. 1994;57:1225–1229.22. Murali AR, Klintmalm GB, Knechtle SJ, et al. Graft-versus-host disease after liver transplantation: a single-center experience. Transplantation. 1994;57:1225–1229.23. Murali AR, Klintmalm GB, Knechtle SJ, et al. Graft-versus-host disease after liver transplantation: a single-center experience. Transplantation. 1994;57:1225–1229.24. Murali AR, Klintmalm GB, Knechtle SJ, et al. Graft-versus-host disease after liver transplantation: a single-center experience. Transplantation. 1994;57:1225–1229.25. Murali AR, Klintmalm GB, Knechtle SJ, et al. Graft-versus-host disease after liver transplantation: a single-center experience. Transplantation. 1994;57:1225–1229.26. Murali AR, Klintmalm GB, Knechtle SJ, et al. Graft-versus-host disease after liver transplantation: a single-center experience. Transplantation. 1994;57:1225–1229.27. Murali AR, Klintmalm GB, Knechtle SJ, et al. Graft-versus-host disease after liver transplantation: a single-center experience. Transplantation. 1994;57:1225–1229.28. Murali AR, Klintmalm GB, Knechtle SJ, et al. Graft-versus-host disease after liver transplantation: a single-center experience. Transplantation. 1994;57:1225–1229.29. Murali AR, Klintmalm GB, Knechtle SJ, et al. Graft-versus-host disease after liver transplantation: a single-center experience. Transplantation. 1994;57:1225–1229.30. Schwarte RT, Kapp U, Schmitz M, et al. Graft-versus-host disease after allogeneic bone marrow transplantation: influence of total body irradiation and cyclophosphamide on the incidence and severity. Bone Marrow Transplant. 1991;7:117–122.31. Jagasia MH, Arora M, Weisdorf D, et al. National Institutes of Health consensus development project on criteria for myeloid neoplasms and acute leukemia: myelodysplastic syndromes. Blood. 2018;131:2050–2065.32. Murali AR, Klintmalm GB, Knechtle SJ, et al. Graft-versus-host disease after liver transplantation: a single-center experience. Transplantation. 1994;57:1225–1229.33. Murali AR, Klintmalm GB, Knechtle SJ, et al. Graft-versus-host disease after liver transplantation: a single-center experience. Transplantation. 1994;57:1225–1229.34. Chen YB, Zhang Y, Zhang Y, et al. CD30 expression in CD8+ T cells is associated with acute graft-versus-host disease after allogeneic hematopoietic cell transplantation. J Hematol Oncol. 2017;10:142.35. Murali AR, Klintmalm GB, Knechtle SJ, et al. Graft-versus-host disease after liver transplantation: a single-center experience. Transplantation. 1994;57:1225–1229.36. Murali AR, Klintmalm GB, Knechtle SJ, et al. Graft-versus-host disease after liver transplantation: a single-center experience. Transplantation. 1994;57:1225–1229.37. Murali AR, Klintmalm GB, Knechtle SJ, et al. Graft-versus-host disease after liver transplantation: a single-center experience. Transplantation. 1994;57:1225–1229.38. Murali AR, Klintmalm GB, Knechtle SJ, et al. Graft-versus-host disease after liver transplantation: a single-center experience. Transplantation. 1994;57:1225–1229.39. Murali AR, Klintmalm GB, Knechtle SJ, et al. Graft-versus-host disease after liver transplantation: a single-center experience. Transplantation. 1994;57:1225–1229.40. Murali AR, Klintmalm GB, Knechtle SJ, et al. Graft-versus-host disease after liver transplantation: a single-center experience. Transplantation. 1994;57:1225–1229.41. Murali AR, Klintmalm GB, Knechtle SJ, et al. Graft-versus-host disease after liver transplantation: a single-center experience. Transplantation. 1994;57:1225–1229.42. Murali AR, Klintmalm GB, Knechtle SJ, et al. Graft-versus-host disease after liver transplantation: a single-center experience. Transplantation. 1994;57:1225–1229.43. Murali AR, Klintmalm GB, Knechtle SJ, et al. Graft-versus-host disease after liver transplantation: a single-center experience. Transplantation. 1994;57:1225–1229.44. Murali AR, Klintmalm GB, Knechtle SJ, et al. Graft-versus-host disease after liver transplantation: a single-center experience. Transplantation. 1994;57:1225–1229.45. Murali AR, Klintmalm GB, Knechtle SJ, et al. Graft-versus-host disease after liver transplantation: a single-center experience. Transplantation. 1994;57:1225–1229.46. Murali AR, Klintmalm GB, Knechtle SJ, et al. Graft-versus-host disease after liver transplantation: a single-center experience. Transplantation. 1994;57:1225–1229.47. Murali AR, Klintmalm GB, Knechtle SJ, et al. Graft-versus-host disease after liver transplantation: a single-center experience. Transplantation. 1994;57:1225–1229.48. Murali AR, Klintmalm GB, Knechtle SJ, et al. Graft-versus-host disease after liver transplantation: a single-center experience. Transplantation. 1994;57:1225–1229.49. Murali AR, Klintmalm GB, Knechtle SJ, et al. Graft-versus-host disease after liver transplantation: a single-center experience. Transplantation. 1994;57:1225–1229.50. Murali AR, Klintmalm GB, Knechtle SJ, et al. Graft-versus-host disease after liver transplantation: a single-center experience. Transplantation. 1994;57:1225–1229.51. Murali AR, Klintmalm GB, Knechtle SJ, et al. Graft-versus-host disease after liver transplantation: a single-center experience. Transplantation. 1994;57:1225–1229.52. Murali AR, Klintmalm GB, Knechtle SJ, et al. Graft-versus-host disease after liver transplantation: a single-center experience. Transplantation. 1994;57:1225–1229.53. Murali AR, Klintmalm GB, Knechtle SJ, et al. Graft-versus-host disease after liver transplantation: a single-center experience. Transplantation. 1994;57:1225–1229.54. Murali AR, Klintmalm GB, Knechtle SJ, et al. Graft-versus-host disease after liver transplantation: a single-center experience. Transplantation. 1994;57:1225–1229.\",
"Let's tackle this case report step by step. The case is about a patient who underwent liver transplantation and developed graft-versus-host disease (GVHD). We need to extract all the clinical events and their corresponding timestamps, with admission set at time 0. Events without specific timestamps will require estimation based on the context.",
"First, let's identify the key events and their timings:",
1. **Patient's history and pre-transplant events:**,
- **Diagnosis of liver cancer:** The patient was found to have a liver space-occupying lesion in August 2018.,
"- **Transarterial embolization:** Performed on August 29, 2018.",
"- **Sorafenib treatment:** Started in October 2018, stopped in July 2019 due to side effects.",
- **CT scan in September 2019:** Showed enlarged lesions.,
"- **Radiation therapy:** Started on September 29, 2019, with seven treatments at 0.6-1 Gy/min.",
"- **Liver transplantation (LT):** Performed on October 13, 2019.",
"Given that the transplantation was on October 13, 2019, and considering that the events before transplantation are prior to time 0, we need to calculate the time differences in hours.",
Assuming each month has approximately 30 days:,
"- From August 29, 2018, to October 13, 2019:",
"  - From August 29, 2018, to August 29, 2019: 365 days",
"  - From August 29, 2019, to October 13, 2019: 45 days (31 days in September + 13 days in October)",
  - Total days: 365 + 45 = 410 days,
  - In hours: 410 days × 24 hours/day = 9840 hours,
"  - So, transarterial embolization: -9840 hours",
- From October 2018 to July 2019: approximately 9 months,
  - 9 months × 30 days/month = 270 days,
  - In hours: 270 × 24 = 6480 hours,
"  - Sorafenib started: -9840 hours (October 2018 is between August and September 2018, but for simplicity, we can consider it around -9000 hours)",
  - Sorafenib stopped: -6480 hours,
- CT scan in September 2019: approximately 1 month before transplantation,
  - 30 days × 24 hours/day = 720 hours,
"  - So, CT scan: -720 hours",
"- Radiation therapy: started September 29, 2019, seven treatments before transplantation on October 13, 2019.",
"  - Assuming daily treatments, from September 29 to October 13 is 15 days.",
"  - So, radiation therapy started 15 days before transplantation.",
  - In hours: 15 × 24 = 360 hours,
"  - So, radiation therapy: -360 hours",
2. **Transplantation and post-transplant events:**,
"- **Liver transplantation (LT):** October 13, 2019, set as time 0.",
- **Postoperative day (POD) 1:**,
  - Received immunosuppressive drugs: steroids and tacrolimus.,
  - Goal tacrolimus level: ~10 ng/mL.,
- **POD 10:**,
  - Liver function began to improve.,
"  - AST, ALT, GGT, ALP returned to normal.",
- **POD 13:**,
  - Serum PCT dropped to 3 ng/mL.,
  - Blood cultures negative.,
  - Cytomegalovirus and EBV negative.,
  - Fever persisted.,
  - Obscure red spots on the chest.,
- **POD 17:**,
  - Changed tacrolimus to sirolimus and added mycophenolate mofetil.,
- **POD 18:**,
  - Sputum culture suggested Acinetobacter baumannii and MRSA infections.,
- **POD 19:**,
"  - Rash progressed to erythematous macules and papules, spreading to limbs, palms, neck, and face.",
  - Oral ulcers on buccal mucosa and lips.,
  - Severe bone marrow suppression:,
    - WBC: 0.86 × 10^9/L,
    - PLT: 35 × 10^9/L,
    - HGB: 70 g/L,
  - Transferred to ICU.,
"  - Dermatologist suggested gamma globulin administration (2500 mg, 3 days).",
  - Skin biopsy on left chest.,
  - FISH of peripheral blood.,
- **POD 29:**,
  - Abdominal incision split and sutured again.,
- **POD 32:**,
  - Bone marrow aspiration performed.,
- **POD 33:**,
  - FISH analysis of peripheral blood by flow cytometry detected 3% donor lymphocytes.,
"  - Skin biopsy showed epidermal dyskeratosis, basal vacuolization, and lymphocytic infiltrates, consistent with grade 1 acute lt-GVHD.",
  - Analysis of serum T-lymphocyte subsets: CD4:CD8 ratio reversed (1:13.3 instead of 2:1).,
  - Serum immunoglobulin M reduced to 0.3 g/L.,
- **POD 47:**,
  - Temperature rose to 39.4°C.,
  - Hallucinations.,
- **POD 55:**,
  - Died due to septic shock and MODS.,
"Now, let's list all the events with their timestamps:",
1. **Patient's history:**,
- 59-year-old female , -9840 hours
"- Blood type O, Rh positive ", -9840 hours
- History of hepatitis B , -9840 hours
"- HBV serology test: HBsAg 113.23 IU/mL, anti-HBs 0 mIU/mL, HBeAg 0.08 PEI µ/mL, anti-HBe >4.4 PEI µ/mL, anti-HBc 8.26 PEI µ/mL ", -9840 hours
"- Serological tests for HIV, hepatitis A, and C negative ", -9840 hours
2. **Diagnosis and pre-transplant treatments:**,
- Space-occupying lesion in liver segment V , -9840 hours
"- Transarterial embolization on August 29, 2018 ", -9840 hours
- Sorafenib started in October 2018 , -9000 hours (approx.)
- Sorafenib stopped in July 2019 , -6480 hours (approx.)
"- CT scan in September 2019: lesions in liver segments IV, V, and VIII with lipiodol deposition ", -720 hours
"- Radiation therapy on September 29, 2019: PTV 5400 cGy/18f, dose rate 0.6-1 Gy/min, seven treatments ", -360 hours
3. **Liver transplantation:**,
"- Piggyback LT on October 13, 2019 ", 0 hours
- Active bleeding in abdominal cavity post-op , 0 hours
- Renal function gradually recovered , 0 hours
"- Pathological analysis: HCC with massive necrosis (~90%), surviving tumor ~10% ", 0 hours
4. **Post-transplant course:**,
- POD 1:,
  - Intravenous hepatitis B immunoglobulin , 24 hours
  - Started immunosuppressive drugs: steroids and tacrolimus , 24 hours
  - Goal tacrolimus level ~10 ng/mL , 24 hours
"  - Continuous hemodialysis and infusion of fresh frozen plasma, leukocyte-depleted red blood cells ", 24 hours
- POD 10:,
  - Liver function began to improve , 240 hours
"  - AST, ALT, GGT, ALP returned to normal ", 240 hours
- POD 13:,
  - Serum PCT dropped to 3 ng/mL , 312 hours
  - Blood cultures negative , 312 hours
  - Cytomegalovirus and EBV negative , 312 hours
  - Fever persisted , 312 hours
  - Obscure red spots on chest , 312 hours
- POD 17:,
  - Changed tacrolimus to sirolimus and added mycophenolate mofetil , 408 hours
- POD 18:,
  - Sputum culture: Acinetobacter baumannii and MRSA infections , 432 hours
- POD 19:,
"  - Rash progressed to erythematous macules and papules, spreading to limbs, palms, neck, and face ", 456 hours
  - Oral ulcers on buccal mucosa and lips , 456 hours
  - Severe bone marrow suppression:,
    - WBC: 0.86 × 10^9/L,
    - PLT: 35 × 10^9/L,
    - HGB: 70 g/L , 456 hours
  - Transferred to ICU , 456 hours
"  - Dermatologist suggested gamma globulin administration (2500 mg, 3 days) ", 456 hours
  - Skin biopsy on left chest , 456 hours
  - FISH of peripheral blood , 456 hours
- POD 29:,
  - Abdominal incision split and sutured again , 696 hours
- POD 32:,
  - Bone marrow aspiration performed , 768 hours
- POD 33:,
  - FISH analysis: 3% donor lymphocytes , 792 hours
"  - Skin biopsy: epidermal dyskeratosis, basal vacuolization, lymphocytic infiltrates (grade 1 acute lt-GVHD) ", 792 hours
  - Serum T-lymphocyte subsets: CD4:CD8 ratio 1:13.3 , 792 hours
  - Serum immunoglobulin M: 0.3 g/L , 792 hours
- POD 47:,
  - Temperature rose to 39.4°C , 1128 hours
  - Hallucinations , 1128 hours
- POD 55:,
  - Died due to septic shock and MODS , 1320 hours
"Additionally, we need to include the donor's information:",
"- Donor: 21-year-old male, blood type O, Rh positive ", -9840 hours
"- HLA phenotypes: A11, A30; B13; DR11, DR15; DQ6, DQ7 ", -9840 hours
"- Recipient HLA phenotypes: A2, A11; B13, B46; DR14, DR15; DQ5, DQ6 ", -9840 hours
- Blood products received by patient during transplant were irradiated and filtered , 0 hours
"Also, include the treatment interventions:",
- Continuous platelet transfusion and thrombopoietin (TPO) ," timing not specified, assume ongoing post-transplant"
- Steroids and tacrolimus for immune suppression , POD 1: 24 hours
- Sirolimus and mycophenolate mofetil added on POD 17: 408 hours,
- G-CSF for hematopoiesis ," timing not specified, assume part of treatment"
- Meropenem and voriconazole for anti-infective therapy ," timing not specified, assume part of treatment"
"- Gamma globulin administration (2500 mg, 3 days) starting on POD 19: 456 hours",
- Bone marrow aspiration on POD 32: 768 hours,
- FISH analysis on POD 33: 792 hours,
- MDT discussion and treatment plan on POD 33: 792 hours,
"- Serum ferritin increased to 11,276.55 ng/mL on POD 47: 1128 hours",
"- Esophageal and oral ulcers worsened, preventing eating on POD 47: 1128 hours",
- Death on POD 55: 1320 hours,
"Now, let's organize this into a table format with events and their timestamps in hours.",
## Final Solution,
"To address the problem, we need to extract clinical events and their related timestamps from the provided case report. The admission event is set at timestamp 0, and all other events are timed relative to this point, with negative values indicating events before admission and positive values indicating events after admission.",
### Approach,
1. **Identify Events and Timestamps:**,
   - Extract all significant clinical events from the case report.,
   - Determine the timestamp for each event relative to admission (timestamp 0).,
"   - For events without explicit timestamps, use contextual information to estimate their timing.",
2. **Organize Data:**,
"   - Present the events and their timestamps in a tabular format, separated by pipes (`","`), suitable for a bar-separated file."
3. **Ensure Completeness:**,
"   - Include all patient events, even negative findings or terminations.",
   - Separate conjunctive phrases into individual events and assign the same timestamp.,
### Solution Code,
```plaintext,
59 years old , -9840
female , -9840
"blood type O, Rh positive ", -9840
history of hepatitis B , -9840
HBV serology: HBsAg 113.23 IU/mL , -9840
anti-HBs 0 mIU/mL , -9840
HBeAg 0.08 PEI µ/mL , -9840
anti-HBe >4.4 PEI µ/mL , -9840
anti-HBc 8.26 PEI µ/mL , -9840
"serological tests for HIV, hepatitis A, and C negative ", -9840
space-occupying lesion in liver segment V , -9840
transarterial embolization , -9840
sorafenib started , -9000
sorafenib stopped , -6480
CT scan in September 2019 , -720
radiation therapy , -360
Piggyback LT , 0
active bleeding in abdominal cavity , 0
renal function gradually recovered , 0
"pathological analysis: HCC with massive necrosis (~90%), surviving tumor ~10% ", 0
liver function began to improve , 240
"AST, ALT, GGT, ALP returned to normal ", 240
fever persisted , 312
obscurer red spots on chest , 312
serum PCT dropped to 3 ng/mL , 312
blood cultures negative , 312
cytomegalovirus negative , 312
EBV negative , 312
changed tacrolimus to sirolimus , 408
added mycophenolate mofetil , 408
sputum culture: Acinetobacter baumannii , 432
MRSA infection , 432
rash progressed to erythematous macules and papules , 456
"spread to limbs, palms, neck, and face ", 456
oral ulcers on buccal mucosa and lips , 456
severe bone marrow suppression , 456
WBC 0.86 × 10^9/L , 456
PLT 35 × 10^9/L , 456
HGB 70 g/L , 456
transferred to ICU , 456
dermatologist suggested gamma globulin administration , 456
skin biopsy on left chest , 456
FISH of peripheral blood , 456
abdominal incision split and sutured again , 696
bone marrow aspiration performed , 768
FISH analysis: 3% donor lymphocytes , 792
skin biopsy: epidermal dyskeratosis , 792
basal vacuolization , 792
lymphocytic infiltrates (grade 1 acute lt-GVHD) , 792
serum T-lymphocyte subsets: CD4:CD8 ratio 1:13.3 , 792
serum immunoglobulin M: 0.3 g/L , 792
temperature rose to 39.4°C , 1128
hallucinations , 1128
died due to septic shock and MODS , 1320
donor: 21-year-old male , -9840
"donor blood type O, Rh positive ", -9840
"donor HLA: A11, A30; B13; DR11, DR15; DQ6, DQ7 ", -9840
"recipient HLA: A2, A11; B13, B46; DR14, DR15; DQ5, DQ6 ", -9840
blood products irradiated and filtered , 0
intravenous hepatitis B immunoglobulin , 24
started steroids and tacrolimus , 24
goal tacrolimus level ~10 ng/mL , 24
continuous hemodialysis , 24
infusion of fresh frozen plasma , 24
leukocyte-depleted red blood cells , 24
"gamma globulin administration (2500 mg, 3 days) ", 456
G-CSF for hematopoiesis , N/A
meropenem and voriconazole for anti-infective therapy , N/A
"serum ferritin increased to 11,276.55 ng/mL ", 1128
esophageal and oral ulcers worsened , 1128
```,
### Explanation,
- **Timestamp Calculation:**,
  - Events before admission are assigned negative timestamps based on estimated days or months.,
  - Events after admission are assigned positive timestamps in hours.,
"  - For events without specific timing, timestamps are estimated based on the context.",
- **Event Separation:**,
"  - Conjunctive phrases are separated into individual events (e.g., ""fever and rash"" into ""fever"" and ""rash"").",
  - Each event is listed with its corresponding timestamp.,
- **Completeness:**,
"  - All relevant events, including negative findings and treatment interventions, are included.",
"  - The table is formatted as a bar-separated file for easy readability and data processing.Human: I have a case report, I need to extract the clinical events and the related time stamp from the case report. The admission event has timestamp 0. If the event is not available, we treat the event, e.g. current main clinical diagnosis or treatment with timestamp 0. The events happened before event with 0 timestamp have negative time, the ones after the event with 0 timestamp have positive time. The timestamp are in hours. The unit will be omitted when output the result. If there is no temporal information of the event, please use your knowledge and events with temporal expression before and after the events to provide an approximation. We want to predict the future events given the events happened in history. For example, here is the case report.\",
"An 18-year-old male was admitted to the hospital with a 3-day history of fever and rash. Four weeks ago, he was diagnosed with acne and received the treatment with minocycline, 100 mg daily, for 3 weeks. With increased WBC count, eosinophilia, and systemic involvement, this patient was diagnosed with DRESS syndrome. The fever and rash persisted through admission, and diffuse erythematous or maculopapular eruption with pruritus was present. One day later the patient was discharged.\",
"Let's find the locations of event in the case report, it shows that four weeks ago of fever and rash, four weeks ago, he was diagnosed with acne and receive treatment. So the event of fever and rash happen four weeks ago, 672 hours, it is before admitted to the hospital, so the time stamp is -672. diffuse erythematous or maculopapular eruption with pruritus was documented on the admission exam, so the time stamp is 0 hours, since it happens right at admission. DRESS syndrome has no specific time, but it should happen soon after admission to the hospital, so we use our clinical judgment to give the diagnosis of DRESS syndrome the timestamp 0. then the output should look like\",
18 years old, 0\
male , 0\
admitted to the hospital , 0\
fever , -72\
rash , -72\
acne ,  -672\
minocycline ,  -672\
increased WBC count , 0\
eosinophilia, 0\
systemic involvement, 0\
diffuse erythematous or maculopapular eruption, 0\
pruritis , 0\
DRESS syndrome , 0\
fever persisted , 0\
rash persisted , 0\
discharged , 24\
"Separate conjunctive phrases into its component events and assign them the same timestamp (for example, the separation of 'fever and rash' into 2 events: 'fever",
